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Abstract 
Loading erythrocytes with Primaquine (PQ) is advantageous. H o w e v e r ,   P Q   p r o d u c e s   d a m a g e  
to erythrocytes through free radicals production. Statins have antioxidant action and are 
involved in protective effect against situation of oxidative stress. Thus the protective effect of 
pravastatin (PS) against PQ induced oxidative damage to human erythrocytes was investigated 
in the current studies upon loading to erythrocytes. 
The erythrocytes were classified into; control erythrocytes, erythrocytes incubated with 
e i t h e r   2   m M   o f   P S   o r   2   m M   o f   P Q ,   a n d   e r y t h r o c y t e s   i n c u b a t e d   with combination of PS plus 
PQ. After incubation for 30 min, the effect of the drugs on erythrocytes hemolysis as well as 
some biomarkers of oxidative stress (none protein thiols, protein carbonyl, thiobarbituric 
acid reactive substance) were investigated.  
O u r   r e s u l t s   r e v e a l e d   t h a t   P S   m a i n t a i n s   t h e s e   b i o m a r k e r s   a t   v a l u e s   s i m i l a r   t o   t h a t   o f   c o n t r o l  
ones. On the other hand, PQ cause significant increases of protein carbonyl by 115% and 
thiobarbituric acid reactive substance by 225% while non-protein thiols were significantly 
d e c r e a s e d   b y   1 1 2   %   c o m p a r e d   w i t h   c o n t r o l   e r y t h r o c y t e s .   P S   p r e -incubation before PQ exerts 
m a r k e d   r e d u c t i o n   o f   t h e s e   m a r k e r s   i n   c o m p a r i s o n   w i t h   P Q   a l o n e .   M o r e o v e r ,   a t   N a C l   c o n-
centrations between 0.4% and 0.8%, PQ causes significant increase   o f   R e d   B l o o d   C e l l s   ( R B C s )  
hemolysis in comparison with the other groups (P<0. 001). Scanning electron micrograph 
indicates spherocytes formation by PQ incubation, but in the other groups the discocyte 
shape of erythrocytes was preserved.  
The reduction of protein oxidation and lipids peroxidation by PS is related to antioxidants 
e f f e c t   o f   t h i s   s t a t i n .   P r e s e r v a t i o n   o f   e r y t h r o c y t e s   f r a g i l i t y   a n d   m o r p h o l o g y   b y   P S   a r e   r e l a t e d   t o  
i t s   f r e e   r a d i c a l s   s c a v e n g i n g   e f f e c t .   I t   i s   c o n c l u d e d   t h a t   p r a v a s t a t i n   h a s   p r o t e c t ive effect against 
erythrocytes dysfunction related any situations associated with increased oxidative stress, 
especially when loaded with PQ. 
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Introduction 
Erythrocytes as drug delivery systems (DDS's) 
are  exposed  to  several  stress  situations.  This  stress 
may  be  either  physical,  hyperosmotic,  as  well  as 
oxidative  stress  [1].  The  erythrocytes  membrane  is 
protected  from  oxidative  damages  by  antioxidant 
e n z y m e s   s y s t e m   s u c h   a s   s u p e r o x i d e   d i s m u t a s e ,   c a t a-
lase,  and glutathione  peroxidase  in  addition  to  non 
enzymatic systems such as glutathione, vitamins A, C 
and E [2]. The alteration of these protective mechan-
isms may result in increase of free radicals production 
that alters the cellular functions [3].  Int. J. Med. Sci. 2010, 7 
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R B C s   a r e   f r equently  exposed  to  oxygen  when 
l o a d e d   w i t h   d r u g s   a s   D D S ' s ,   t h u s   a r e   m o r e   s u s c e p t i b l e  
to  oxidative  damage.  Moreover,  the  hemoglobin  in 
RBCs is a strong catalyst that may initiate oxidative 
damage [4]. Oxidation of erythrocytes leads to signif-
icant  alteratio n s   i n   t h e i r   s t r u c t u r a l   l i p i d s   a s   w e l l   a s  
d e f o r m a t i o n s   o f   t h e   c y t o s k e l e t a l   p r o t e i n s   [ 5 ] .   I n   a d d i-
tion to lipid peroxidation, sulfhydryl groups of pro-
t e i n s   m a y   b e   t a r g e t e d   f o r   o x i d a t i v e   s t r e s s   [ 4 ] .   F u r-
thermore, the decrease of glutathione can enhance the 
tendency of sulfhydryl groups to oxidation [5]. Oxi-
d a t i o n   o f   p r o t e i n s   i n c r e a s e s   t h e   f o r m a t i o n   o f   d i s u l f i d e  
as well as carbonyl groups [6]. 
T o x i c   m a n i f e s t a t i o n s   i n d u c e d   b y   s e v e r a l   d r u g s  
a r e   s h o w n   t o   b e   m e d i a t e d   b y   o x i d a t i v e   s t r e s s   m e-
chanisms.  Involvement  of  reactive  oxygen  species 
( R O S )   h a s   b e e n   d e m o n s t r a t e d   i n   t h e   t o x i c i t y   o f   m a n y  
drugs to erythrocytes [7]. PQ is used for treatment of 
malarial infections and its loading to erythrocytes is 
u s e f u l .   T h e   t h e r a p e u t i c   u s e   o f   t h i s   d r u g   i s   r e s t r i c t e d  
d u e   t o   i t s   t o x i c   side  effects.  PQ  causes  hemolytic 
anemia  especially  in  glucose-6-phosphate  dehydro-
genase deficient patients [8]. The interaction between 
PQ  with  reduced  nicotinamide  dinucleotide  phos-
p h a t e   ( N A D P H )   u n d e r l i e s   m a n y   a s p e c t s   o f   P Q   t o x i c-
ity. Also, the autooxidati o n   o f   P Q   r e s u l t   i n   f o r m a t i o n  
of ROS which leading to oxidative alterations in eryt-
hrocytes [9]. These species not only overwhelm cellu-
lar  antioxidant  defenses  but  also  attack  cellular 
structural molecules, leading to oxidative modifica-
tion of erythrocytes [10]. 
Antioxidants  can  help  in  preservation  of  an 
adequate antioxidant status; therefore, they preserve 
the normal physiological function of living cells by 
protection against reactive oxygen species [11]. Statins 
a r e   t h e   g r o u p   o f   d r u g s   t h a t   l o w e r   t h e   blood choles-
terol level, besides their therapeutic uses of hyperli-
pidemia, inflammation, immunomodulation in addi-
tion to antioxidant effects [12, 13]. Pravastatin (PS) is 
o n e   o f   t h e   s t a t i n s   g r o u p   e f f e c t i v e   i n   t h e   t r e a t m e n t   o f  
hypercholesterolemia. Moreover,   i t   h a s   o t h e r   b e n e f i-
cial effects on several cardiovascular alterations [14]. 
Previously  the  study  demonstrated  that  treatment 
with PS has protective effect against oxidative stress 
[15]. 
The present study was designed to demonstrate 
the protective effect of PS against PQ induced lipids 
peroxidation, proteins oxidation as well as hemolysis 
of  human  erythrocytes  upon  loading.  The  erythro-
c y t e s   a r e   i n c u b a t e d   w i t h   P Q   f o r   3 0   m i n   a n d   i t s   e f f e c t  
on erythrocytes thiobarbituric acid reactive substance 
(TBARS),  protein  carbonyl  (PCO)  as  well  as 
non-protein thiols (NPSH) is determined in presence 
and absence of PS. 
Materials and methods 
Materials 
Pravastatin sodium was gifted by Saudi Phar-
maceutical Industries & Medical Appliances Corpo-
ration  (SPIMACO,  Al–Qassim,  Saudi  Arabia).  Pri-
maquine diphosphate, Ellman’s reagent and thiobar-
bituric  acid,  tetraethoxypropane  were  provided  by 
Sigma Chemical Co., St. Louis, MO, USA. Acetonitrile, 
methanol,  isopropanol,  trichloroacetic  acid  and  so-
dium hydroxide were supplied by Merck Germany. 
2,4–Dinitrophenylhydrazine  and,  Guanidine  hy-
drochloride were obtained from (BDH Chemical Ltd 
Poole UK, and Winlab, UK respectively. A l l   o f   t h e  
remaining  chemicals  used  in  the  studies  are 
commercially available as analytical grade. 
Instrumentation  
S p e c t r o   U V -Vis Split Beam PC (Model UVS-2800, 
Labomed, Inc.); Shaking Water Bath (Julabo SW22); 
C e n t r i f u g e   C T 5   w e r e   u s e d   f o r   t h e  investigation of the 
present  studies  and  COULTER®  LH  780 is used  as 
Hematology Analyzer. 
Specimen collection and erythrocytes isolation 
Blood  samples  were  collected  in  heparinized 
tubes from adult men (ages between 35-40 years) not 
suffered from chronic or acute illness. Informed con-
sent  was  obtained  from  all  donors.  The  blood  was 
centrifuged for 5 min at 1500 rpm. The plasma and 
b u f f y   c o a t   w e r e   r e m o v e d   b y   a s p i r a t i o n   t o   e l i m i n a t e  
leucocytes  and  platelets;  erythrocytes  were  washed 
t h r e e   t i m e s   i n   c o l d   p h o s p h a t e   b u f f e r   s a l i n e   p H   7 . 4  
with  centrifugation  for  5  min  at  1500  rpm [16].  This 
study  was  approved  by  the  research  center  ethics 
co m m i t t e e   o f   C o l l e g e   o f   P h a r m a c y ,   K i n g   S a u d   U n i-
versity, Riyadh, Saudi Arabia.  
Experimental design 
Erythrocytes  suspension  with  hematocrite  ad-
justed at 45% were classified into 4 groups where each 
g r o u p   c o n t a i n s   6   s a m p l e s :   i n   g r o u p   o n e   t h e   e r y t h r o-
cytes  exposed  neither  pravastatin  nor  primaquine 
( c o n t r o l   g r o u p ) .   I n   t h e   s e c o n d   g r o u p ,   t h e   e r y t h r o c y t e s  
w e r e   i n c u b a t e d   w i t h   2 m M   o f   p r a v a s t a t i n .   T h e   e r y t-
h r o c y t e s   w e r e   t r e a t e d   w i t h   2 m M   o f   p r i m a q u i n e   i n   t h e  
t h i r d   g r o u p .   A n d   i n   t h e   f o u r t h   g r o u p   t h e   e r y t h r o c y t e s  
were expo s e d   t o   p r a v a s t a t i n   p l u s   p r i m a q u i n e   2 m M .  
After  30  min,  the  erythrocytes  were  hemolysed  by 
a d d i n g   d i s t i l l e d   w a t e r   ( 1 : 1 ) .   T h e n   t h e   l y s a t e s   w e r e  
used for the following biochemical investigations.  
Assessment of erythrocytes non-protein thiols status 
Erythrocytes  NPSH  were  determined  using 
Ellman’s  reagent,  5,  5-dithiobis  (2-  nitrobenzoate). Int. J. Med. Sci. 2010, 7 
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Protein was precipitated with adding 1:1 volume of 
5%  trichloroacetic  acid  (TCA).  After  centrifugation, 
the supernatant was neutralized with Tris-NaOH and 
NPSH were quantified in supernatant [17]. 
Assessment of erythrocytes protein oxidation  
Protein oxidation erythrocytes were assayed  as 
protein carbonyl according to the method of Levine et 
al. [18]. Proteins were precipitated from RBCs lysates 
b y   a d d i t i o n   o f   1 0 %   T C A   a n d   r e s u s p e n d e d   i n   1 . 0   m l   o f  
2   M   H C l   f o r   b l a n k   a n d   2   M   H C l   c o n t a i n i n g   2 %   2 , 4 - 
dinitrophenyl hydrazine. After incubation for 1 h at 
3 7 ° C ,   p r o t e i n   s a m p l e s   w e r e   w a s h e d   w i t h   a l c o h o l   a n d  
ethyl acetate, and re-precipitated by addition of 10% 
TCA. The precipitated protein was dissolved in 6 M 
guanidine  hydrochloride  solution  and  measured  at 
3 7 0   n m .   C a l c u l a t i o n s   w e r e   m a d e   u s i n g   t h e   m o l a r   e x-
tinction coefficient of 22×103M−1 cm−1 and expressed 
a s   n m o l   c a r b o n y l s   f o r m e d   p e r   m g   p r o t e i n .   T o t a l   p r o-
tein in RBC pellet was assayed a c c o r d i n g   t o   t h e   m e-
t h o d   o f   L o w r y   e t   a l .   [ 1 9 ]   u s i n g   b o v i n e   s e r u m   a l b u m i n  
as standard. 
Assessment of erythrocytes lipids peroxidation  
Thiobarbituric acid reactive substance (TBARS) 
was determined as indicator of lipid peroxidation in 
erythrocytes by a spectrophotometric method [20]. A 
m i x t u r e   o f   2 0 0   μ L   o f   8 %   s o d i u m   d o d e c y l   s u l f a t e ,   2 0 0  
μL of 0.9% thiobarbituric acid and 1.5 ml 20% acetic 
a c i d   w a s   p r e p a r e d .   2 0 0   μ L   o f   R B C s   l y s a t e   a n d   1 . 9   m l  
d i s t i l l e d   w a t e r   w e r e   a d d e d   t o   c o m p l e t e   t h e   v o l u m e   o f  
4   m l .   A f t e r   b o i l i n g   f o r   1   h ,   t h e   m i x t u r e   w a s   c o o l e d ,  
a n d   5   m l   o f   n-b u t a n o l   a n d   p y r i d i n e   ( 1 5 : 1 )   s o l u t i o n   w a s  
added to it. This mixture was then centrifuged at 5000 
r p m   f o r   1 5   m i n   a n d   t h e   a b s o r b a n c e   w a s   m e a s u r e d   a t  
5 3 2   n m .   Q u a n t i f i c a t i o n   o f   M D A   l e v e l s   w a s   p e r f o r m e d  
using tetraethoxypropane as the standard. 
Determination of erythrocytes hemolysis 
Erythrocytes hemolysis was determined by os-
motic  fragility  behavior  using  different  NaCl  solu-
tions.  A  25  μL  of  blood  samples  from  all  studied 
groups were added to a series of 2.5 ml saline  solu-
t i o n s   ( 0 . 0   t o   0 . 9   %   o f   N a C l ) .   A f t e r   g e n t l e   m i x i n g   a n d  
s t a n d i n g   f o r   1 5   m i n   a t   r o o m   t e m p e r a t u r e   t h e   e r y t-
hrocytes suspensions were centrifuged at 1500 rpm for 
5  min.  The  absorbance  of  released  hemoglobin  into 
the supernatant was measured at 540 nm [21]. 
Scanning electron microscopy (SEM) 
Morphological differences between control and 
drug exposed erythrocytes was evaluated using JEOL 
JSM-6380 LA. Scanning electron microscope was used 
to  evaluate  the  morphological  differences  between 
normal,  pravastatin  and  primaquine  exposed  eryt-
hrocytes.  All  groups  of  erythrocytes  were  fixed  in 
buffered gluteraldehyde. Aldehyde was drained and 
r i n s e d   3   t i m e s   e a c h   o f   5   m i n   i n   p h o s p h a t e   b u f f e r   a n d  
post-fixed in osmium tetroxide for 1 h. After this, the 
samples were rins e d   i n   d i s t i l l e d   w a t e r   a n d   t h e n   d e-
hydrated using a graded ethanol series; 25, 50, 75, 100 
and another 100% each for 10 min. Then the samples 
were  rinsed  in  water,  removed,  mounted  on  stabs, 
coated with gold and viewed under the SEM. 
Statistical analysis 
The statistical differences between groups were 
a n a l y z e d   b y   o n e   w a y   A N O V A   f o l l o w e d   b y   T U K E Y  
K r a m e r   m u l t i p l e   c o m p a r i s o n   t e s t ,   u s i n g   G r a p h P a d  
P r i s m   S o f t w a r e   v   5 . 0 1 .   T h e   v a l u e s   a t   P   <   0 . 0 5   w e r e  
chosen as statistically significant. 
Results 
Our results revealed that incubation of erythro-
cytes  for  30  min  with  pravastatin  at  concentration 
2mM do not change the NPSH level in erythrocytes 
(57.13 ± 6.50) versus erythrocytes free drug (58.93 ± 
4.81).  While  exposure  of  erythrocytes  to  2  mM  pri-
m a q u i n e   a l o n e   w a s   r e s u l t e d   i n   a   s i g n i f i c a n t   d e c r e a s e  
of NPSH content (26.05 ± 2.58) compared with control 
erythrocytes as well as pravastatin exposed erythro-
cytes.  Pretreatment  of  erythrocytes  with  2mM  of 
pravastatin  before  primaquine  exposure  preserve 
NPSH  level  (54.03  ±  4.84)  regard i n g   t o   R B C s   i n c u-
bated with PQ alone, Figure 1. 
I n   t h i s   s t u d y ,   t h e r e   i s   c o n s i d e r a b l e   e l e v a t i o n   o f  
PCO  content  of  erythrocytes  treated  with  2mM  of 
primaquine by about 115% in relation to either control 
erythrocytes or erythrocytes treated with pravastatin. 
On the other hand, erythrocytes treated with 2mM of 
pravastatin exert no change in PCO level in relation to 
control  one.  Moreover,  prior  incubation  of  erythro-
cytes  with  pravastatin  keep  away  from  primaquine 
i n d u c e d   e l e v a t i o n   o f   P C O   c o n t e n t   b y   a b o u t   1 1 3 % ,   s ee 
Figure 2. 
I n   r e s p e c t   t o   T B A R S   o u r   r e s u l t s   s h o w e d   t h a t   i n-
cubation  of  erythrocytes  with  PQ  exert  significant 
e l e v a t i o n   o f   T B A R S   b y   a b o u t   2 2 5 %   v e r s u s   e r y t h r o-
cytes free drug as well as erythrocytes supplemented 
with pravastatin. Furthermore, pravastatin treatment 
a t   t h e   s a m e   t i m e   w i t h   p r i m a q u i n e   p r e s e r v e s   t h e   e r y t-
h r o c y t e s   T B A R S   c o n t e n t   a t   v a l u e   n e a r   t h a t   o f   t h e   c o n-
trol group see Figure 3. 
Hemolysis  profile  of  control  erythrocytes  and 
erythrocytes incubated with pravastatin, primaquine 
alone or in combination is revealed in Table 1. The 
results of this work demonstrated that, NaCl at 0-0.2% 
concentration range, there is no significant difference 
in  the  erythrocytes  hemolysis  in  percent  between Int. J. Med. Sci. 2010, 7 
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primaquine, pravastatin as  well as  control  erythro-
cytes.  Conversely,  NaCl  at  0.3-0.9%  concentration 
range,  there  is  significant  increase  in  the  percent  of 
RBCs hemolysis for primaquine in comparison with 
the other groups (P<0. 001).  
Table 1: Hemolysis profile of control erythrocytes and 
erythrocytes exposed to either PRV or PQ at concentra-
tion 2 m mole /L 
NaCl g/L  % of erythrocytes hemolysis 
   Control   PS   PQ   PS+ PQ 
1.0  94.8 ± 9.24  98.4 ± 8.65  99.5 ± 8.03  95.2 ± 9.63 
2.0  88.2 ± 8.70  89.2 ± 9.53  97.9 ± 6.05  90.2 ± 7.63 
3.0  62.8 ± 14.3  63.2 ± 10.8  83.5 ± 12.5 *a  64.4 ± 8.50 *b 
4.0  27.8 ± 5.16  31.3 ± 7.64  51.5 ± 13.3**a  37.3 ± 6.43*b 
5.0  21.3 ± 7.50  22.3 ± 9.49  40.6 ± 8.71a  23.8 ± 9.82 *b 
6.0  11.7 ± 3.39  12.9 ±3.28  27.4 ± 6.34 ***a  14.2 ± 2.00***b 
7.0  5.18 ± 1.90  6.79 ±2.22  16.2 ± 3.61 ***a  9.05 ± 2.00***b 
8.0  2.88± 1.78  2.51 ± 0.86  9.07 ± 2.60 ***a  3.96±1.54 ***b 
9.0  1.28 ± 0.55  1.42± 1.01  2.76 ± 1.04 *a  2.28 ±0.85 
Data expressed as mean ± SD, six samples in each group  
a, significantly increased from control or pravastatin (PS) 
b, significantly decreased from primaquine (PQ) 
*, P value ≤ 0.05 
**, P value ≤ 0.01 
***, P value ≤ 0.05 
 
I n   t h i s   s t u d y ,   o u r   d a t a   a l s o   s h o w   t h a t   t h e   m i n i-
mum hemolysis of erythrocytes (1.28%, 1.42%, 2.76 % 
and 2.28%) was observed at NaCl concentration of 0.9 
%   f o r   c o n t r o l ,   p r a v a s t a t i n ,   p r i m a q u i n e   a n d   t h e i r  
combinations  respectively.  On  another  side  the 
m a x i m u m   h e m o l y s i s   o f   9 4 . 8 %   f o r   c o n t r o l   e r y t h r o-
cytes,  98.4%  for  pravastatin,  99.5%  for  primaquine 
and  95.2%  for  the  combination  between  pravastatin 
and primaquine was occurred at NaCl concentration 
of 0.1%. 
Typical  micrographs  of  erythrocytes  obtained 
f o l l o w i n g   e x p o s u r e   t o   d r u g s   h a s   b e e n   d e p i c t e d   i n  
Figure  4.  Control  erythrocytes  and  erythrocytes  in-
cubated (for 30 min) with pravastatin, primaquine, as 
well  as  their   c o m b i n a t i o n s   a t   2   m M   c o n c e n t r a t i o n s  
were screened for any observable morphological al-
terations using scanning electron microscope (SEM). 
Our  results  showed  the  spherocytes  formation  as  a 
result of primaquine incubation. B u t   i n   c o n t r o l   g r o u p ,  
pravastatin  as  well  as  pravastatin  plus  primaquine 
treatment  showed  the  normal  discocyte  shape  of 
erythrocytes was preserved.  
 
 
 
 
Figure 1: Effect of pravastatin and primaquine on erythrocytes non protein thiols (NPSH) level. Int. J. Med. Sci. 2010, 7 
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Figure 2: Effect of pravastatin and primaquine on erythrocytes protein carbonyl level. 
 
 
 
 
Figure 3: Effect of pravastatin and primaquine on erythrocytes thiobarbituric acid reactive substance (TBARS) level. Int. J. Med. Sci. 2010, 7 
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F i g u r e   4 : Scanning   e l e c t r o n   m i c r o s c o p e   g r a p h i n g   o f   ( a )   c o n t r o l   R B C ,   ( b )   R B C   i n c u b a t e d   w i t h   2   m M   P S ,   ( c )   R B C   e x p o s e d   t o  
2 mM of PQ (d) RBCs exposed to same concentration of PS plus PQ. Note spherocytes formation on case of primaquine 
treatment(c). Magnification x5.500. 
 
Discussion 
Erythrocytes  have  been  proposed  as  real-time 
biomarkers  in  many  diseases.  However,  changes  of 
RBCs have been detected in a number of human pa-
thologic  conditions  or  exposure  to  xenobiotics  dis-
playing oxidative stress.  So  that  the  preservation  of 
erythrocytes functions is believable to protect against 
t h e   d e v e l o p m e n t   o f   m a n y   d i s e a s e s .   I n   t h i s   s t u d y   w e  
have investigated the protective effect of pravastatin 
against primaquine induced oxidative stress in hu-
man erythrocytes.  
N P S H   m o s t l y   G S H ,   c y s t e i n e ,   c o e n z y m e   A   a n d  
other  thiols  play  important  role  in  cytoprotection 
a g a i n s t   o x i d a t i v e   s t r e s s   [ 22]. Therefore, the decrease of 
NPSH levels in erythrocytes, making them more sus-
ceptible to oxidative insult. Nonetheless, primaquine 
mediate  oxidative  stress  through  interaction  with 
N A D P H ,   a s   w e l l   a s   a u t o -oxidation leading to genera-
tion of ROS such as hydrogen peroxide, superoxide as 
well as hydroxide radicals [23]. The significant de-
crease of NPSH in erythrocytes after incubation with 
p r i m a q u i n e   i s   d u e   t o   i n t e r a c t i o n   o f   R O S   w i t h   N P S H  
o x i d i z i n g   t h e m .   O n   t h e   c o n t r a r y ,   s t a t i n s   h a v e   a b i l i t y  
to inhibit the production of ROS as well as maintains 
the antioxidants activity in the cell [24]. Moreover it 
has  been  reported  that  supplementation  of  antioxi-
dants preserve the NPSH from oxidative damage [25]. 
Therefore,  pravastatin  can  protect  the  erythrocytes 
NPSH against primaquine induced oxidation. These 
findings  are  in  agreement  with  the  previous  study 
established  that  antioxidants  supplementation  pre-
serve cellular thiols and maintains the cells integrity 
[26]. 
Oxidation  of  proteins  can  introduce  carbonyl 
groups at some amino acids residues such as lysine, 
arginine,  proline,  and  threonine  in  the  polypeptide Int. J. Med. Sci. 2010, 7 
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chains [27]. PCO level was assessed to evaluate pri-
maquine-m e d i a t e d   p r o t e i n   o x i d a t i v e   d a m a g e .   I n   o u r  
observation there is marked elevation of erythrocytes 
PCO level by primaquine exposure is noticed. These 
findings  are  in  accordance  with  pervious  study  re-
p o r t e d   t h a t   i n   v i t r o   e x p o s u r e   o f   R B C s   t o oxidants re-
sulted in damaging of protein in addition to increase 
P C O   f o r m a t i o n   [ 2 7 ] .   T h i s   m a y   s u g g e s t   t h a t   o x i d a n t  
drugs increase free radicals production in red blood 
c e l l s   a n d   d e c r e a s e   t h e   a c t i v i t i e s   o f   a n t i o x i d a n t   e n-
zymes  [26].  Furthermore,  proteinases  that  protect 
erythrocytes  proteins  by  degrading  the  oxidatively 
d a m a g e d   p r o t e i n s   a r e   l o s t   d u r i n g   o x i d a t i v e   s t r e s s   [ 2 8 ] .  
Pravastatin  treatment  protects  the  erythrocytes 
against primaquine induced protein oxidation. These 
results  are  with  the  same  observation  stated  that 
pravastatin maintains catalase activity; however cat-
a l a s e   i s   o n e   o f   t h e   i m p o r t a n t   a n t i o x i d a n t   e n z y m e s   i n  
erythrocytes [29] .   T h e   r e d u c t i o n   o f   N P S H   b y   p r i m a-
quine is a clear indication of oxidative stress, leading 
to protein oxidation as well a s   i n c r e a s e   o f   e r y t h r o c y t e s  
TBARS as indicator for lipids peroxidation. Pravasta-
tin  inhibits  the  oxidative  stress  induced  by  prima-
q u i n e   t h r o u g h   n o r m a l i z a t i o n   o f   T B A R S   a s   w e l l   a s  
PCO levels. However, statins protects against lipids 
peroxidation in different situation of oxidative stress 
[30].  Likewise,  there  are  some  reports  which  sug-
gested  that  antioxidants  are  able  to  decrease  the 
oxidative stress caused by drugs or chemicals [31]. 
Osmotic  fragility  is  used  to  display  structural 
changes  of  the  RBC  membrane when  they  are  sub-
jected to osmotic stress [32]. In the present study, the 
susceptibility of erythrocytes to hemolysis in presence 
o f   p r i m a q u i n e   w a s   g r e a t e r   t h a n   t h a t   o f   c o n t r o l   i n   a d-
dition  to  pravastatin  treated  erythrocytes. This find-
i n g   a r e   s i m i l a r   t o   t he  previous  study  reported  that 
exposure  of  antimalarial  drugs  to  high  iron  level 
f o u n d   i n   t h e   R B C s   c r e a t e   f r e e   r a d i c a l s   t h a t   a r e   h i g h l y  
destructive  to  erythrocytes  plasma  membrane  [32]. 
Furthermore,  increase  of  protein  oxidation  in  eryt-
hrocytes as well as a significant decrease in sulfhydryl 
content  clearly  indicate  the  presence  of  oxidative 
stress in erythrocytes membrane [33]. Increased oxid-
ative stress may be responsible for the increased fra-
gility  of  primaquine  treated  erythrocytes.  Further-
more,  free  radicals  can  overwhelm  the  capacity  of 
antioxidants  enzymes  to  maintain  and  keep  up  the 
membrane integrity [34].  
The major alteration in the shape of erythrocytes 
i s   t h e   s p h e r o c y t e s   f o r m a t i o n   i n   t h e   p r e s e n c e   o f   p r i-
maquine.  These  observations  are  supported  by  the 
work d o n e   b y   P r a s a n t h i   e t   a l . ,   i n   2 0 0 5   w h i c h   r e p o r t e d  
that the shape changes of erythrocytes are induced by 
a d d i t i o n   o f   s o m e   d r u g s .   S p h e r o c y t e s   f o r m a t i o n   m a y  
b e   d u e   t o   a l t e r a t i o n   o f   s t r u c t u r a l   p r o t e i n   o f   t h e   m e m-
brane as a result of protein oxidation [35].  
F i n a l l y ,   i t   c a n   b e   c o n c l u d e d   t h a t   i n c r e a s e d   p r o-
tein and lipid oxidation during PQ exposure desta-
b i l i z e   t h e   m e m b r a n e   o f   e r y t h r o c y t e s   l e a d i n g   t o   s i g-
nificant increase of erythrocytes hemolysis. Pravasta-
tin treatment can protect erythrocytes against prima-
quine  induced  oxidative  damage  due  to  antioxidant 
action. Furthermore, it is concluded that pravastatin 
can  be  used  to  preserve  the  erythrocytes  functions 
during conditions associated with increased oxidative 
stress such as drug induced oxidative damage.  
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